Stock Evaluator: Aura Biosciences, Inc. (AURA)

Aura Biosciences, Inc. AURA

$6.87 -0.11 -1.58%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 791,133
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics AURA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $715.0 $203.5 43%
Shares Out (Mil) 111.1 55.2 64%
Institutional Ownership 98.4% 93.3% 78%
Float (Mil) 74.7 40.4 55%
Beta 0.44 1.05 24%
Avg Daily Volume (000s) 765 569 65%
Price Change
(52-week)
27.2% 38.8% 78%
Growth AURA Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (36.8%) (10.7%) 11%
EPS (5yr) 53.6% 15.4% 94
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 15.0% (15.7%) 72%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials AURA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $40 na
Net Income (TTM) (Mil) ($137) ($44) 9%
EPS (TTM) ($1.607) ($1.400) 16%
Operating Cash Flow (TTM) (Mil) ($109) ($35) 6%
Net Cash Flow (TTM) (Mil) ($6) $-0 35%
Long-Term Debt (Q1) (Mil) $13 $4 30%
Enterprise Value (Q1) (Mil) $516 $142 35%
Valuation AURA Industry
Median
Percentile
(All Stocks)
P/B 2.48 1.96 65%
P/E na 16.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios AURA Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (53.5%) (47.0%) 10%
ROE (61.7%) (51.8%) 13%
Liabilities to Assets 10.6% 29.6% 6%
F-Score 4 3 33%

Aura Biosciences, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors